Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line. [electronic resource]
Producer: 20100927Description: 1090-7 p. digitalISSN:- 1029-2403
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Arsenic Trioxide
- Arsenicals -- pharmacology
- Blotting, Western
- Bone Marrow Cells -- pathology
- Cell Adhesion -- drug effects
- Cell Survival -- drug effects
- Cells, Cultured
- Coculture Techniques
- Cytarabine -- pharmacology
- Daunorubicin -- pharmacology
- Dose-Response Relationship, Drug
- Down-Regulation -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- Humans
- Inhibitory Concentration 50
- Integrin beta1 -- metabolism
- K562 Cells
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- blood
- Oxides -- pharmacology
- Stromal Cells -- drug effects
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.